Tune in as Precision BioLogic’s Chief Scientific Officer F. Jon Geske, PhD and Marketing Director Ian Burns discuss advances in hemophilia A testing and treatment:

• Learn about current and emerging bispecific antibody treatments such as Mim8, and the importance of bovine chromogenic FVIII assays
• Listen as Tara Quinton, R&D Scientist and part of Precision BioLogic’s Chromogenic FVIII assay design team, discusses the assay’s expanded utility along with new data that secured the assay’s FDA clearance
• Hear first-hand from Julie Tange, Principal Developer, Hematopathology at the Special Coagulation Laboratory, Mayo Clinic, about her experiences with our fully bovine assay
• Ask questions to learn how you and your lab can be ready for the future of hemophilia A testing

Wednesday October 22, 2025, 1–2 p.m. Eastern